Mutational analysis of T315I in patients with chronic myeloid leukemia who did not respond to second-generation tyrosine kinase inhibitors

Al-Jadir, Riyam Qusay Ibrahim; Alalsaidissa, Jaffar N. Jaffar

doi:10.4103/ijh.ijh_31_20

Cited by 1 publication

(2 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this study, the ratio of male to female was 1.14:1 which is the same as that of Alves et al (12) study (1.14:1), but it is less than that reported by Larson et al (13) study (1.7:1), and close to other Iraqi studies (1.38:1 and 1.3:1) reported by Khazaal et al (14) , while in contrast to another local study conducted by AL-Jader et al (15) where the ratio was reversed (1:1.27).…”

Section: Discussionsupporting

confidence: 68%

“…The age range in our study (41-60 years) was comparable with Larson et al (13) who included patients in the range of 18-70 years, in Alves et al (12) study was 18-78 years and in Peng et al (16) study was 14-70 years. But it was different from AL-Jader et al (15) who reported a range of 23-63 years, while Abdullah et al (17) found 44/130 (33.85%) of patients belonged to the age category 31-40 years.…”

Section: Discussionmentioning

confidence: 61%

See 1 more Smart Citation

Association of Microrna-153-3p Expression in Response to Treatment with Imatinib in Patients with Chronic Myeloid Leukemia

Abbas¹,

Al-Rubaie²

2023

The Egyptian Journal of Hospital Medicine

View full text Add to dashboard Cite

Background: It is thought that the susceptibility of chronic myeloid leukemic (CML) cells to imatinib (IM) is increased by high miR-153-3p expression. Aim: To establish the association of miR-153-3p expression with treatment response to IM in CML patients. Methods: Sixty CML patients were included and divided into two groups consistent with their response to treatment whether sensitive or resistant to IM. Ten healthy normal participants were enrolled as control group. RNA was extracted from serum to work out miR-153-3p expression utilizing real-time quantitative reverse transcription polymerase chain reaction. The primers were supplied by Macrogen Inc. Results: 27 patients were sensitive to imatinib and 33 were resistant to imatinib. The ratio of male to female was 1.14:1. The bulk (58%) of patients were within the age range of 41-60 years. Weight and gender did not significantly differ between the two patient groups. The mean patients' CT of miR-153-3p was significantly above the control group and the sensitive group. The mean DCT value in resistant group was significantly above that of the sensitive group while insignificantly above that of the control group. The mean DDCT in resistant group was significantly higher than that of the sensitive group. The miR-153-3p expression showed significantly lower fold change than the sensitive group. Conclusion:There is miR-153-3p expression downregulation in resistant CML patients indicating unresponsiveness to treatment with imatinib.

show abstract